Could self-management challenge pharmacotherapy as a long-term treatment for uncomplicated lower urinary tract symptoms?

Current Opinion in Urology

Volumn 14, Issue 1, 2004, Pages 7-12

  Brown, Christian T ^a   Emberton, Mark ^b  

^a ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^b INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

Author keywords

BPH; LUTS; Pharmacotherapy; Self management; Watchful waiting

Indexed keywords

ALCOHOL; CAFFEINE;

ARTHRITIS; BEHAVIOR; DIABETES MELLITUS; HUMAN; LIFESTYLE; LONG TERM CARE; MANAGEMENT; MEDICAL PRACTICE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT WITHDRAWAL; URINARY TRACT DISEASE; AGED; CHRONIC DISEASE; COMPARATIVE STUDY; DIET; DRUG COMBINATION; HOSPITALIZATION; MALE; METHODOLOGY; MICTURITION DISORDER; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SELF CARE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DIET; DRUG THERAPY, COMBINATION; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SELF CARE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; URINATION DISORDERS;

EID: 2342562422     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200401000-00002     Document Type: Review

References (51)

1. Chapple CR. BPH disease management. Eur Urol 1999; 36 (Suppl 3):1-6.
2. Hunter M. Urinary symptoms: prevalence and severity in British men aged 55 years and over. J Epidemiol Community Health 1984; 48:569-575.
3. Abrams P. New words for old: lower urinary tract symptoms for 'prostatism'. BMJ 1994; 308:929-930.
4. Hirst G, Butler J, Lajoie V, et al. Clinical Practice Guidelines 2000: The management of uncomplicated lower urinary tract symptoms in men. National Health and Medical Research Council of Australia, February 2000. http:// www.health.gov.au/nhmrc/publications/pdf/cp42.pdf. [Accessed November 2001]
5. Roberts RO, Jacobsen SJ, Jacobsen DJ, et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000; 163:107-113.
6. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155:595-600.
7. Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61:267-273. This is a useful review of many of the larger BPH studies focusing on BPH as a progressive disease.
8. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001; 39:390-399.
9. Wright EJ, Fang J, Metter EJ, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Long-itudinal Study of Aging. J Urol 2002; 167:2484-2488.
10. Marberger MJ, Anderson JT, Nickel JC, et al. Prostate volume and serum PSA as predictors of acute urinary retention. Eur Urol 2000; 38:563-568.
11. Thomas AW, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 2000; 85:57-68.
12. Abrams P. Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns [abstract]. J Urol 2003; 167 (Suppl. 4):266.
13. Djavan B, Marberger M. Meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in men with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36:1-13.
14. Verhamme KMC, Dieleman JP, Bleumink GS, et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: The Triumph Project. Eur Urol. 2003; 44(5):539-545
15. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995; 45:406-413.
16. Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long term efficacy and safety in hypertensive and normotensive patients. The Multicentre Study Group. J Urol 1997; 157:625-530.
17. Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group. Eur Urol 1999; 36:609-620.
18. de la Rosette J, Kortmann B, Rossi C, et al. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 2002; 167:1734-1739. This interesting paper reports on the long-term retreatment rates in men on alpha-blockers and what are the risk factors for retreatment.
19. Marberger MJ. Long term effects of finsteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled multicentre study. PROWESS Study Group. Urology 1998; 51:677-395.
20. McConnell JD, Bruskewitz R, Walsh PC, et al. The effect of finasteride on the risk of acute retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long Term Efficacy and Safety Study Group (PLESS) N Engl J Med 1998; 338:557-563. Prior to the Medical Therapy of Prostatic Symptoms (MTOPS) study Proscar Long-term Efficacy and Safety Study (PLESS) remained the largest and longest BPH study of finsteride and showed over a 4-year period BPH progression to AUR was prevented with finasteride. Interestingly it also gave an insight into changes in prostatic growth over time in the placebo arm.
21. Yang Q, Abrams P, Donovan J, et al. Transurethral resection or incision of the prostate and other therapies: a survey of treatments for benign prostatic obstruction in the UK. BJU Int 1999; 84:640-645.
22. Richards T. Partnership with patients. BMJ 1998; 316:85-86.
23. Lorig K, Gonzalez VM, Laurent DD, Morgan L. Arthritis self-management program variations: three studies. Arthritis Care Res 1998; 11:448-454.
24. Wysocki T, Harris MA, Wilkinson K, et al. Self-management competence as a predictor of outcomes of intensive therapy or usual care ir, youth with type 1 diabetes. Diabetes Care 2003; 26:2043-2047.
25. Caplin DL, Creer TL. A self-management program for adult asthma III. Maintenance and relapse of skills. J Asthma 2001; 38:343-356.
26. Lorig K. Conceptual basis for the chronic disease self-management study. In: Vickie Baker, editor. Outcome measures for Health Education and other Health Care interventions. Thousand Oaks: Sage Publications; 1996. pp 1-10.
27. Bandura A. Self-efficacy mechanism in physiological activation and health-promoting behaviour. In: J Madden, editor. Adaptation, learning and effect. Raven Press, New York; 1991. pp 229-270.
28. Brown CT, van der Meulen J, Mundy AR, Emberton M. Lifestyle and behavioural interventions for men on watchful waiting with uncomplicated lower urinary tract symptoms: A national multidisciplinary survey. BJU Int 2003; 92:53-57.
29. Managing lower urinary tract symptoms in men. Drug Ther Bull 2003; 41:18-21. Which? 2003, Collier J Ed. 2 Marylebone Road, London NW1 4DF
30. Referral Advice. A guide to appropriate referral from general to specialist services. London: National Institute for Clinical Excellence; 2001.
31. de la Rosette J, Alivizatos G, Madersbacher S, et al. Watchful waiting. Drukkerij Gelderland editors. European Urological Association Guidelines on BPH. Arnhem, The Netherlands, European Association of Urology, pub; 2002. pp. 39-41. This provides up-to-date and informative clinical practice guidelines from the European Urological Association. It contains a large bibliography supporting recommendations on assessment, diagnosis and management.
32. Barry MJ, Fowler FJ, Mulley AG, et al. Patient reactions to a program designed to facilitate patient participation in treatment decisions for BPH. Med Care 1995; 33:771-782.
33. Murray E, Davis H, See Tai S, et al. Randomised controlled trial of an interactive multimedia decision aid on BPH in primary care. BMJ 2001; 323:1-6.
34. Young JM, Muscatello DJ, Ward JE. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000; 85:1037-1048.
35. Brown CT, O'Flynn E, van der Meulen J, et al. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? BJU Int 2003; 91:30-33.
36. Abrams P, Kevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scan J Urol and Neph 1996; 179:47-53.
37. Valtin H. Drink at least eight glasses of water a day. Really? Is there scientific evidence for "8 x 8"? Am J Physiol Regul Integr Comp Physiol 2002; 238:993-1004. In this exhaustive and compelling read all published data regarding fluid intake is assessed in the context of health. Many epidemiological data are presented.
38. Griffiths DJ, McCracken PN, Harrison GM, Gormley EA. Relationship of fluid intake to voluntary micturition and urinary incontinence in geriatric patients. Neurourol Urodyn 1993; 12:1-7.
39. Reynard J. Fluid balance therapy of nocturia in women. Int Urogyn J Pelvic Floor Dysfunct 1999; 10:43-48.
40. Creighton M, Stanton SL. Caffeine: does it affect your bladder? Br J Urol 1990; 66:613-614.
41. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy ageing men. J Clin Epidemiol 2001; 54:935-944.
42. Gass R. Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake. BJU Int 2002; 90:649-654.
43. Prezioso D, Catuogno C, Galassi P, et al. Life-style in patients with LUTS suggestive of BPH. Eur Urol 2001; 40:9-12.
44. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs 2002; 11:560-565.
45. Donovan JL, Kay HE, Peters TJ, et al. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: ICS-'BPH' study. Br J Urol 1997; 80:712-721.
46. Paterson J, Pinnock CB, Marshall VR. Pelvic floor exercises as a treatment for post-micturition dribble. Br J Urol 1997; 79:892-897.
47. Burgio KL. Influence of behaviour modification on overactive bladder. Urology 2002; 60 (Suppl 5a):72-76.
48. Mattiason A, Blaakaer J, Hoye K, Wein AJ. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 2003; 91:54-60.
49. Flanigan RC, Reda DJ, Wasson JH, et al. Five year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160:12-16.
50. Kadow C, Fennely RC, Abrams P. Prostatectomy or conservative management in the treatment of benign prostatic hypertrophy. Br J Urol 1988; 61:432-434.
51. Weingarten SR, Henning JM, Badamgarav E, et al. Interventions used in disease management programmes for patients with chronic illness: which ones work? Meta-analysis of published reports. BMJ 2002; 325:925-933.